EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypofractionated Radiotherapy Elicits Tumor‐Derived APOC2 to Drive Inflammatory Monocyte Differentiation and Potentiate Anti‐Tumor Immunity in Colorectal Cancer

Qian Xu iD, Haihong Wang, Mingjie Li iD, Zhenwei Zou, Lichao Liu iD, Linlin Zheng, Donglin Kang iD, Ruijie Sun, Cheng Cheng, Ke Xu, Jinghua Ren, Lan Zhang und 5 weitere

Advanced Science · 15.11.2026

DOI: 10.1002/advs.78746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.11.2026. Verfasst von Qian Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Clinical Research Initiative Program of Union Hospital, National Natural Science Foundation of China, Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypofractionated radiotherapy (HFRT) combined with immunochemotherapy holds promise for overcoming immune resistance in microsatellite‐stable (MSS) locally advanced rectal cancer (LARC). However, the mechanisms underlying its effects remain unclear. Using secretome profiling, ATAC‐seq, bulk and single‐cell RNA sequencing, we investigated how HFRT remodels the tumor immune microenvironment. APOC2 was induced by HFRT, and higher post‐treatment serum APOC2 levels were associated with pathologic complete response (pCR) to HFRT‐based neoadjuvant immunochemotherapy. Mechanistically, HFRT reduced ATF3 expression, relieving its repression of the APOC2 promoter and increasing tumor‐cell APOC2 secretion. APOC2 activated lipoprotein lipase, increased free fatty acid production, enhanced type I interferon signaling, and promoted the differentiation of Ly6A + inflammatory monocytes. These monocytes exhibit specialized MHC class I antigen‐presentation programs that bolster CD8 + T‐cell effector functions. Clinically, the APOC2 nomogram demonstrated consistent discriminative ability for pCR across the discovery and internal validation cohorts. Therapeutic supplementation with recombinant APOC2 or APOC2‐loaded nanoliposomes (APOC2@NL) sensitized murine tumors to HFRT plus PD‐1 blockade. These findings position APOC2 as a functional mediator between radiotherapy‐induced metabolism and antitumor immunity, offering a promising biomarker and a preclinical therapeutic proof of concept for LARC.

Schlagwörter

Stichwörter der Autor:innen

LARCapolipoprotein C‐IIhypofractionated radiotherapyimmunotherapyinflammatory monocyte

Autor:innen und Institutionen

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei International Scientific and Technological Cooperation Base of Precision Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, China.

ORCID-Profile: Qian Xu, Mingjie Li, Lichao Liu, Donglin Kang, Tao Zhang

Förderung

  • Key Clinical Research Initiative Program of Union Hospital
  • National Natural Science Foundation of China
  • Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund
  • CSCO Research Fund
  • National Key Technology Research and Development Programme of Hubei Province
  • Natural Science Foundation of Hubei Province of China-Hengrui Medicine Joint Fund for Innovative Development
  • Shenzhen Basic Research Fund
  • "Jiebang Guashuai" Project for Clinical Specialties of Wuhan Union Hospital

Zitieren

APA

Xu, Q., Wang, H., Li, M., Zou, Z., Liu, L., Zheng, L., Kang, D., Sun, R., Cheng, C., Xu, K., Ren, J., Zhang, L., Han, C., Zhang, P., Tao, K., Lin, Z., & Zhang, T. (2026). Hypofractionated Radiotherapy Elicits Tumor‐Derived APOC2 to Drive Inflammatory Monocyte Differentiation and Potentiate Anti‐Tumor Immunity in Colorectal Cancer. Advanced Science. https://doi.org/10.1002/advs.78746

Vancouver

Xu Q, Wang H, Li M, Zou Z, Liu L, Zheng L, et al. Hypofractionated Radiotherapy Elicits Tumor‐Derived APOC2 to Drive Inflammatory Monocyte Differentiation and Potentiate Anti‐Tumor Immunity in Colorectal Cancer. Advanced Science. 2026. doi:10.1002/advs.78746

BibTeX
@article{Xu2026,
  author = {Xu, Qian and Wang, Haihong and Li, Mingjie and Zou, Zhenwei and Liu, Lichao and Zheng, Linlin and Kang, Donglin and Sun, Ruijie and Cheng, Cheng and Xu, Ke and Ren, Jinghua and Zhang, Lan and Han, Chaoqun and Zhang, Peng and Tao, Kaixiong and Lin, Zhenyu and Zhang, Tao},
  title = {Hypofractionated Radiotherapy Elicits Tumor‐Derived APOC2 to Drive Inflammatory Monocyte Differentiation and Potentiate Anti‐Tumor Immunity in Colorectal Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78746}
}
Kostenlos starten →